1. Home /
  2. Biotechnology

Biotechnology

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Jim Cramer and our other experts discuss oil prices, bullish market signals and medical diagnostic plays.

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

TheStreet spoke with John Carreyrou, a reporter with The Wall Street Journal, who brought to light Theranos' issues in a bombshell article in 2015.

3 Fascinating Companies Using AI to Forge New Advances in Healthcare

3 Fascinating Companies Using AI to Forge New Advances in Healthcare

Welcome to the future of healthcare. That future includes the use of AI to improve patient outcomes.

3 Cutting-Edge Biotech Stocks That Can Double in Value

3 Cutting-Edge Biotech Stocks That Can Double in Value

These three "strong buy" biotech stocks are primed for outsized growth in the next 12 months. Here's why.

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.

Can a Bold Name Change Help Valeant Escape Its Tarnished Reputation?

Can a Bold Name Change Help Valeant Escape Its Tarnished Reputation?

Valeant will become Bausch Health Cos. this summer. Here's what that could mean for the company as it continues to recover from controversy.

Takeda Pharmaceutical Agrees $62.4 Billion Takeover of Shire

Takeda Pharmaceutical Agrees $62.4 Billion Takeover of Shire

Japan's biggest drugmaker, Takeda Pharmaceutical Co., looks to have wrapped up its bid to buy Dublin-based Shire plc for $62.4 billion in cash and shares.

3 Hot Reads on Stocks From TheStreet's Top Columnists

3 Hot Reads on Stocks From TheStreet's Top Columnists

Jim Cramer and our other experts look at Estee Lauder, 'special dividends' and oncology stocks.

3 Hot Reads on Stocks From TheStreet's Top Columnists

3 Hot Reads on Stocks From TheStreet's Top Columnists

Jim Cramer and our other experts discuss tech stock Skyworks, Buffett's Apple move, and possible Biotech M&A's.

BeyondSpring CEO Reveals Novel Tumor Therapy

BeyondSpring CEO Reveals Novel Tumor Therapy

The company is working on regulatory approvals in the U.S. and China.